Prokidney (PROK) Asset Writedowns and Impairment (2024 - 2025)
Prokidney's (PROK) quarterly Asset Writedowns and Impairment came in at $318000.0 in Q3 2025, down 94.03% year-on-year from $5.3 million in Q3 2024, and down 94.03% on a QoQ basis from $5.3 million in Q3 2024.
Prokidney (PROK) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Prokidney (PROK) has 2 years of Asset Writedowns and Impairment data on file, last reported at $318000.0 in Q3 2025.
- On a quarterly basis, Asset Writedowns and Impairment fell 94.03% year-over-year to $318000.0 in Q3 2025; TTM through Dec 2025 was $318000.0, a 94.03% decrease from a year earlier, with the FY2025 full-year figure at $318000.0, down 94.03% from the prior year.
- Asset Writedowns and Impairment for Q3 2025 stood at $318000.0, down from $5.3 million in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for PROK reached as high as $5.3 million in Q3 2024 and fell as low as $318000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Prokidney | 96.00 Mn | 96.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 318,000.00 |
| Sep 30, 2025 | 318,000.00 |
| Sep 30, 2024 | 5.32 Mn |
| Sep 30, 2024 | 5.32 Mn |